Sex hormones in head and neck cancer: Current knowledge and perspectives

Abstract

Head and neck cancer (HNC) is an increasing problem worldwide.

Oral carcinogenesis is a highly complex multifocal process.

Molecular mechanisms contributing to initiation and progression of head and neck squamous cell carcinoma are still poorly known.

Endocrine microenvironment is another imperative factor beside other well-documented risk factors like tobacco smoking, alcohol and infections in causing cancers of head and neck.

These endocrine hormones play a role in tumor progression in case of cancers characteristically expressing sex hormone receptors, and it has been proven that these receptors also reside outside the sex organs in the larynx and lungs.

However, the role of sex hormones in HNC is controversial, and few studies have been conducted to delineate their role in HNC.

So, this review article is an attempt to draw an attention towards the potential role of sex hormones in pathogenesis of HNC and potential therapeutic modalities to prevent onset and progression of cancer.

About this publication.

See also:

- The Di Bella Method (A Fixed Part - Bromocriptine/Cabergoline);

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;

- Oesophageal squamocellular carcinoma: a complete and objective response;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.